Alemtuzumab is a Formidable Therapy for Cancer and Multiple Sclerosis


alemtuzumabKnown as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune cells to help destroy the cancer cells. An intravenous infusion, administered over roughly two hours is how Alemtuzumab is dispensed. Some patients experience much longer infusion periods, such as five or six hours, particularly if it is their first treatment with Alemtuzumab. Dosing is dependent on weight and condition, with most patients receiving daily infusions in a titrated fashion. After a standard best in care dose is reached many patients are administered infusions of Alemtuzumab three times a week for roughly twelve weeks. Adverse effects may occur, and include reports of low platelet counts, fever, nausea and vomiting. The FDA approved Alemtuzumab in 2001 for the treatment of chronic leukemias and lymphoma.

A new FDA approval for Alemtuzumab was announced in November 2014, with a nod given to Genzyme’s Lemtrada, for the treatment of multiple sclerosis (MS). Indicated specifically for patients with relapsing forms of MS, Lemtrada (Alemtuzumab) is reserved for patients who have had inadequate responses to at least two current therapies for MS. Two successful trials of Alemtuzumab, which compared Lemtrada to Rebif in patients with relapsing MS, showed Alemtuzumab was more effective. This duo of randomized trials involved just about 1,500 patients with refractory multiple sclerosis and included over 6,400 patient-years of follow-up safety studies. While Alemtuzumab does include a boxed warning as the MS drug Lemtrada, the risk of fatal autoimmune conditions is uncommon. However, as of now Lemtrada is only available via a restricted distribution program in the United States. The dosing schedule of Alemtuzumab as Lemtrada for patients with remitting MS is unique, with two treatments dispensed annually. The first administration is given for five consecutive days through an intravenous infusion. The second dosage does not occur until roughly twelve months later, and is dispensed for three consecutive days. Side effects noted from study participants who received Lemtrada included nausea, dizziness, rash, fatigue and flushing. Lemtrada (Alemtuzumab) was approved in the EU in September of 2013 to treat multiple sclerosis.

The potential for Alemtuzumab for treating a wide swath of life threatening illnesses is great. The latest indication for this formidable drug will be a viable option for the 2.3 million people suffering from multiple sclerosis around the globe. In the United States there are approximately 400,000 people who have been diagnosed with MS. LGM Pharma can assist clients as a supplier/distributor of the Alemtuzumab API, CAS # 216503-57-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: